Biolexis Therapeutics
Biotechnology, Salt Lake City, Utah, 84095, United States, 1-10 Employees
Who is BIOLEXIS THERAPEUTICS
MoleculernTM The Next Evolution in Drug Discovery Screening each MoleculernTM fragment against a curated protein target library has resulted in 600K real/empirical data points and scaffol...
Read More
-
Headquarters: Salt Lake City, Utah, 84095, United States
-
Date Founded: 2021
-
Employees: 1-10
-
Revenue: Under $1 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 541714 |
Show More
Does something look wrong? Fix it. | View contact records from BIOLEXIS THERAPEUTICS
Biolexis Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Biolexis Therapeutics
Answer: Biolexis Therapeutics's headquarters are located at Salt Lake City, Utah, 84095, United States
Answer: Biolexis Therapeutics's official website is https://biolexistx.com
Answer: Biolexis Therapeutics's revenue is Under $1 Million
Answer: Biolexis Therapeutics's SIC: 2836
Answer: Biolexis Therapeutics's NAICS: 541714
Answer: Biolexis Therapeutics has 1-10 employees
Answer: Biolexis Therapeutics is in Biotechnology
Answer: Biolexis Therapeutics contact info: Phone number: Website: https://biolexistx.com
Answer: MoleculernTM The Next Evolution in Drug Discovery Screening each MoleculernTM fragment against a curated protein target library has resulted in 600K real/empirical data points and scaffold-like compounds that can be used to design new drug candidates and to accelerate the discovery process. Our empirically rich MoleculernTM technology is rapidly creating, discovering, and developing novel pre-clinical to clinical stage agents. Our modern chemical biology approach coupled with our advanced machine learning and AI-backed platform accelerates discoveries by mapping hot-spots, computing ligand properties and building accurate empirical models which translate into active, safe, and efficacious novel chemical entities (NCEs) of future medicines. Biolexis is developing better and safer drugs faster through MoleculernTM: Accelerates drug discovery/development to new therapeutics Shortens the path to the clinic to increase the probability of success Expedites to First-In-Human (FIH) clinical trials Facilitates delivery of medicines to patients worldwide
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month